Scholar Rock reports FY 2024 net loss of $2.47/share; BLA submitted for apitegromab in SMA

Scholar Rock Holding Corp

2024-FY EPS reported -$2.47

Net loss $246.3M ( $2.47 /share) vs $165.8M ( $1.99 /share) in FY 2023; zero revenue.
Cash, equivalents & marketable securities $437.3M; expanded credit facility adds up to $150M in tranches.
BLA for apitegromab in SMA submitted Jan 2025; US launch planned 4Q 2025; EU MAA expected 1Q 2025.
Phase 2 EMBRAZE topline data (apitegromab+tirzepatide in obesity) expected 2Q 2025; IND for SRK-439 in 3Q 2025.
COO/CFO Ted Myles departing; search for new CFO; Lisa Wyman appointed CTQO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.